J&J wins FDA OK for their nasal spray ver­sion of a par­ty drug, now ap­proved for treat­ment-re­sis­tant ma­jor de­pres­sion

There it is. 

De­spite some se­ri­ous clin­i­cal fail­ures, the FDA has ap­proved J&J’s new drug es­ke­t­a­mine for ma­jor de­pres­sion, which will now hit the mar­ket as Spra­va­to.

An in­tranasal for­mu­la­tion of ke­t­a­mine, a horse tran­quil­iz­er that is bet­ter known in par­ty cir­cles as Spe­cial K, the drug won a warm as­sess­ment by FDA in­sid­ers as well as an over­whelm­ing vote in its fa­vor by a pan­el of out­side ex­perts or­ga­nized by the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.